Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. The company is headquartered in Eden Prairie, Minnesota and currently employs 389 full-time employees. The company also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the demanding requirements. Its segments include Medical Device and IVD. Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral and coronary. IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.
根據最新的財務報表(Form-10K),Hua Hong Grace Semiconductor Limited 的總資產為 $0,淨isProfitable}為 $0
SRDX 的關鍵財務比率是什麼?
Hua Hong Grace Semiconductor Limited 的流動比率為 0,淨利潤率為 0,每股銷售為 $0。
Surmodics Inc 的收入按細分市場或地理位置如何劃分?
Hua Hong Grace Semiconductor Limited 最大收入來源為 Semiconductor Wafers,在最近的收益報告中收入為 16,547,023,645。就地區而言,China and Hong Kong 是 Hua Hong Grace Semiconductor Limited 的主要市場,收入為 14,190,700,725。
Surmodics Inc 是否盈利?
無,根據最新的財務報表,Hua Hong Grace Semiconductor Limited 的淨損失為 $0